GlassScriptPhysician profile
Michael J Heise
NPI 1003804162
$3,861.07
in general payments reported to CMS, 2019-2025
26 companies · $1,613 in 2025
The $1,613 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.28 · 2021: $177 · 2022: $469 · 2023: $765 · 2024: $799 · 2025: $1,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,177.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,146.40 | 2022-2025 | Injectafer |
| Novo Nordisk INC | $496.16 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $417.38 | 2021-2025 | |
| Pfizer INC. | $398.78 | 2019-2025 | |
| Amgen INC. | $197.19 | 2022-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $174.86 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $146.95 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $132.64 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $124.43 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Exact Sciences Corporation | $98.39 | 2023-2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $93.62 | 2019-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $51.98 | 2025 | Rexulti |
| Acadia Pharmaceuticals INC | $47.43 | 2025 | Nuplazid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.27 | 2022-2023 | Xifaxan, Trulance |
| Astellas Pharma US INC | $38.85 | 2025 | Veozah |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $32.05 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.03 | 2022 | |
| Neurocrine Biosciences, INC. | $28.16 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.31 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $24.74 | 2022 | |
| Axsome Therapeutics, INC. | $23.99 | 2025 | Symbravo |
| Tonix Medicines, INC. | $18.06 | 2025 | Tonmya |
| Dexcom, INC. | $17.88 | 2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $16.89 | 2025 | Eliquis |
| Currax Pharmaceuticals LLC | $16.33 | 2025 | Onzetra Xsail, Contrave |
| Nestle Healthcare Nutrition INC. | $15.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Heise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.